NCT04560218View on ClinicalTrials.gov

Sublingual vs Intrauterine MISOPROSTOL Plus Oxytocin Infusion for Prevention of Post-cesarean Hemorrhage in High Risk Pregnant Women: A Double-blind Placebo RCT

PHASE3CompletedINTERVENTIONAL

Enrollment

135

Participants

Timeline

Start Date

October 30, 2020

Primary Completion Date

July 31, 2021

Study Completion Date

September 10, 2021

Conditions

To Compare Efficacy Intrauterine vs Sublingual MISOPROSTOL in Addition to Oxytocin in Reducing Blood Loss of Post-cesarean Section in High Risk Women

Interventions

DRUG

sublingual Misoprostol

apply drug by Anesthesiologist

DRUG

Intrauterine Misoprostol

apply drug by surgeon at uterine cornu

Trial Locations (1)

10400

Rajavithi hospital, Bangkok

All Listed Sponsors

lead

Department of Medical Services Ministry of Public Health of Thailand

OTHER_GOV

NCT04560218 - Sublingual vs Intrauterine MISOPROSTOL Plus Oxytocin Infusion for Prevention of Post-cesarean Hemorrhage in High Risk Pregnant Women: A Double-blind Placebo RCT | Biotech Hunter | Biotech Hunter